The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma

BACKGROUND: Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC. Therefore, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamura, Atsushi, Uojima, Haruki, Chuma, Makoto, Shao, Xue, Hidaka, Hisashi, Nakazawa, Takahide, Take, Akira, Sakaguchi, Yoshihiko, Numata, Kazushi, Kako, Makoto, Nozaki, Akito, Azuma, Shintaro, Horio, Kazue, Kusano, Chika, Atsuda, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396897/
https://www.ncbi.nlm.nih.gov/pubmed/35999529
http://dx.doi.org/10.1186/s12885-022-10002-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396897/
https://www.ncbi.nlm.nih.gov/pubmed/35999529
http://dx.doi.org/10.1186/s12885-022-10002-x

Ejemplares similares